Boehringer Ingelheim’s nintedanib has been designated a Promising Innovative Medicine for the treatment of malignant pleural mesothelioma (MPM) by the UK Medicine and Healthcare Products Regulatory Agency.
This indicates that the regulator considers nintedanib is promising candidate for the UK’s Early Access to Medicines Scheme, which gives patients with life threatening or seriously debilitating conditions access to medicines before they are approved for use in Europe.
“This is fantastic news and the right decision taking into account the risk/benefit profile of nintedanib from a very credible Phase II trial,” said Professor Dean Fennell, Chair of Thoracic Medical Oncology at the University of Leicester and University Hospitals of Leicester NHS Trust, UK, commenting on the decision.
MPM is a relatively rare but aggressive thoracic cancer that is often rapidly progressive once clinically apparent, most cases of which are linked to long-term exposure to asbestos.
In 2014 there were 2,502 cases of MPM in the UK, and patients have a poor prognosis, with median survival ranging from eight -14 months from diagnosis.[Article continues at original source]
Asbestos-Mesothelioma Case Evaluation Form
Free. Confidential. No Obligation.